Wound Care Biologics Market Report 2025

The wound care biologics market size has grown strongly in recent years. It will grow from $1.91 billion in 2024 to $2.08 billion in 2025 at a compound annual growth rate (CAGR) of 9.2%. The growth in the historic period can be attributed to clinical evidence and studies, regulatory framework development, wound care market evolution, limited treatment options, research and development efforts.

The wound care biologics market size is expected to see strong growth in the next few years. It will grow to $2.96 billion in 2029 at a compound annual growth rate (CAGR) of 9.2%. The growth in the forecast period can be attributed to focus on personalized medicine, rise in healthcare expenditure, value-based healthcare models, growing demand for advanced therapies, regulatory support and approvals. Major trends in the forecast period include regenerative medicine emphasis, bioengineered skin substitutes, innovative delivery systems, rise in chronic wound management, patient-centric care.

The increasing prevalence of diabetes is expected to drive the growth of the wound care biologics market in the near future. Diabetes is a chronic metabolic condition characterized by elevated blood glucose levels, which can lead to severe damage to the heart, blood vessels, eyes, kidneys, and nerves over time. Biological wound care products help prevent excessive water loss, heat loss, and the loss of proteins and electrolytes, while also minimizing contamination. They facilitate autolytic debridement and promote the formation of a granular wound layer. The high prevalence of diabetes is a key factor contributing to the growth of the wound care biologics market. For instance, in June 2024, the National Health Service (NHS), a UK-based government department, reported an increase in diabetes cases among individuals under 40, rising from 173,166 in 2022 to 216,440 in 2023. This significant growth indicates a troubling trend in this age group and highlights the rapid rise in diabetes prevalence among younger populations. Thus, the high prevalence of diabetes is driving the expansion of the wound care biologics market.

The rising number of surgical procedures is expected to drive the growth of the wound care biologics market in the future. Surgical procedures involve medical interventions that require incisions or the use of instruments to treat a patient's medical condition. Wound care biologics typically include living cells, growth factors, or other biological materials that promote the natural healing process. As the volume of surgical procedures increases, so does the interest in advanced wound care solutions that can expedite the healing of surgical wounds, reduce complications, and improve overall patient outcomes. For example, in October 2023, the Organization for Economic Co-operation and Development, a France-based intergovernmental organization, reported an 8.4% increase in cataract surgeries in the Czech Republic, with a total of 142,670 procedures in 2022, up from 131,612 in 2021. Thus, the increase in surgical procedures is fueling the growth of the wound care biologics market.

Major companies in the wound care biologics market are concentrating on developing advanced materials, such as bioengineered, electrospun synthetic polymer matrices, to improve wound healing efficacy and support tissue regeneration. These bioengineered matrices facilitate faster wound healing and enhanced tissue regeneration by acting as scaffolds that encourage cellular migration and growth. For example, in October 2024, Royal Biologics, a US-based orthobiologics and life sciences company, introduced two innovative products at the symposium on advanced wound care: the Peak Powder Collagen Matrix, which enhances healing in various wounds by creating a gel-like barrier that supports tissue regeneration, and ElectroFiber 3D, a bioengineered matrix that promotes cellular migration and reduces healing times. These advancements significantly influence the wound care biologics market by addressing the increasing demand for effective healing solutions.

Skin graft development is a major focus for key companies in the wound care biologics market, aiming to gain a competitive edge. Skin grafting involves a surgical procedure where healthy skin is transplanted from one body area (donor site) to another area that has lost its protective covering due to injury, surgery, burns, or other traumatic conditions. For instance, in July 2022, Tides Medical, a US-based biotechnology company, launched Artacent AC, a tri-layer skin graft designed for treating complex or challenging wounds. With a three-layer structure (amnion-chorion-amnion), it surpasses traditional dual-layer products, being three times stronger and two times thicker. Artacent AC is developed to enhance handling and application to wound sites, offering clinicians an improved solution for complex patient wounds in various medical conditions such as diabetic foot ulcers, chronic wounds, burns, Mohs surgery, and other surgical applications. The product boasts a longer shelf life at room temperature, eliminating the need for refrigeration, and can be placed on either side facing the wound.

In July 2023, Coloplast, a US-based healthcare company, acquired Kerecis for $1.3 billion. Through this acquisition, Coloplast aims to strengthen its presence in the advanced wound care market by integrating Kerecis's innovative fish skin technology. This move helps Coloplast enter the high-growth U.S. biologics sector, enhance its revenue and gross margins, and raise its long-term organic growth guidance from 7% to 9% to 8% to 10%, all while allowing Kerecis to operate as a standalone business unit. Kerecis is an Iceland-based company specializing in regenerative medicine solutions using fish skin to treat chronic wounds and surgical applications.

Major companies operating in the wound care biologics market include Integra Lifesciences Corporation, Organogenesis Inc., Smith and Nephew plc, Wright Medical Group NV, MiMedx Group Inc., Kerecis AG, Amnio Technology LLC, Anika Therapeutics Inc., ACell Inc., Derma Sciences Inc., Soluble Systems Pvt. Ltd., Medline Industries LP, Solsys Medical LLC, Zimmer Biomet Holdings Inc., MLM Biologics Inc., Tissue Genesis LLC, Stryker Corporation, Marine Polymer Technologies Inc., Bioventus Inc., Mölnlycke Health Care AB, Lynch Biologics LLC, Skye Biologics Holdings LLC, Osiris Therapeutics Inc., Vericel Corporation, TissueTech Inc., PolarityTE Inc., Avita Medical Limited, Celularity Inc., Human Regenerative Technologies LLC, PolyRemedy Inc.

North America was the largest region in the wound care biologics market in 2024. Asia-pacific is expected to be the fastest-growing region in the global wound care biologics market report during the forecast period. The regions covered in the wound care biologics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the wound care biologics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Wound care biologics refer to bioengineered products specifically designed for the treatment of non-healing wounds in the lower extremity. These biologics are gaining prominence in wound care due to their effective control of secretions and protective properties against bacterial infections.

The primary products within the field of wound care biologics include biologic skin substitutes and topical agents. Biologic skin substitutes play a crucial role in wound healing and have proven to be highly beneficial within the medical industry. Also known as tissue-engineered products or artificial skin, biologic skin substitutes are biological substances that facilitate wound healing by promoting the generation of new tissues. Wound care biologics are commonly utilized to treat various types of wounds, including ulcers, surgical wounds, traumatic wounds, and burns. The end users of these biologics include hospitals, Ambulatory Surgical Centers (ASCs), burn centers, and wound clinics.

The wound care biologics software market research report is one of a series of new reports that provides wound care biologics software market statistics, including wound care biologics software industry global market size, regional shares, competitors with a wound care biologics software market share, detailed wound care biologics software market segments, market trends and opportunities, and any further data you may need to thrive in the wound care biologics software industry. This wound care biologics software market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The wound care biologics market consists of revenues earned by entities by providing wound care services such as surgical and traumatic wounds, burns chronic wounds and acute Wounds. The market value includes the value of related goods sold by the service provider or included within the service offering. The wound care biologics market also includes sales of surgical equipment's, medical tape, sponges, cotton pads which are used in providing wound care biologics services. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.